Missing data for other key variables, such as TMB, KRAS mutations, and co-mutational status (e.g., TP53), prevented us from conducting a powered analysis that includes these variables, and we know that increasing TMB levels are associated with immune cell infiltration and an inflammatory T-cell-mediated response, resulting in increased sensitivity to PD-1/PD-L1 blockade in NSCLC across PD-L1 expression subgroups, while KRAS mutations confer worse outcomes on immunotherapy [24,25]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.